Research on Advanced Intervention using Novel Bone marrOW stem cell (RAINBOW): Phase I, trial of autologous bone marrow stromal cell transplantation in patients with acute ischemic stroke
Stroke is a leading cause of death and disability, and despite intensive research, few treatment options exist. However, a recent breakthrough in cell therapy is expected to reverse the neurological sequelae of stroke. Although some pioneer studies on the use of cell therapy for treating stroke have been reported, certain problems remain unsolved. Recent studies have demonstrated that bone marrow stromal cells (BMSCs) have therapeutic potential against stroke. We investigated the use of autologous BMSC transplantation as a next-generation cell therapy for treating stroke.
『 血管内血栓除去治療と局所脳冷却灌流治療の併用についての探索的臨床研究』－COOL IVR Study－
近年、血管内治療による血栓除去療法が脳梗塞の急性期治療として有効であるというランダム化研究の結果が相次いで報告されました。しかし、一部の症例では虚血再灌流傷害によると思われる著しい脳浮腫、出血性梗塞を来たし、予後不良となってしまうことがあります。我々は動物モデルを用いた基礎研究において、経動脈的な局所脳冷却灌流治療が脳梗塞を縮小させることを明らかにしてきました。この研究成果を生かし、今回の研究では、主幹動脈閉塞のある脳梗塞で血管内血栓除去治療を行う症例において、今回我々が考案した局所脳冷却灌流治療を行い、この治療法の安全性を検討することを一番の目的としています。
Nation-wide registry and bio-bank for Moyamoya disease
The number of clinical research papers published worldwide on moyamoya disease (MMD) has increased recently. However, the majority of the literature comprises retrospective single-center studies collecting data on small numbers of patients. Several multi-center studies are ongoing in Japan; however, the current data are insufficient for comprehensively outlining the various characteristics of MMD. To enhance our knowledge on epidemiologic, vascular, and genetic aspects of MMD, a prospective multicenter registry will be established in Japan that will help to streamline clinical research as well as improve clinical treatments and long-term outcomes. Patients with MMD or secondary moyamoya syndrome referred to the participating centers will be invited to the registry. Demographic and physiological parameters, along with neuroimaging data will be collected chronologically. Clinical events, including neurological, medical, and surgical interventions will be recorded. Whole blood samples will be collected. Extra- and intra-cranial vascular tissue, and/or cerebrospinal fluid will also be collected from patients who undergo surgical revascularization. These biospecimens will be stored at the repositories and utilized for genome-wide association studies for identifying genetic variants, as well as tissue-specific proteomic, and/or molecular analyses. The registry will provide descriptive statistics on functional outcomes, surgical techniques used, medications, and neurological events stratified according to patients’ clinical characteristics. We expect this study to provide novel insights in the management of MMD patients and design better therapies.
